Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters











Publication year range
1.
Clin Transl Oncol ; 22(9): 1603-1610, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32048158

ABSTRACT

PURPOSE: Since the role of resistin was evaluated only in patients with non-small cell lung cancer (NSCLC) not treated with immunotherapy, we aimed to evaluate levels of resistin during immunotherapy (nivolumab) and its prognostic role with regard to OS. METHODS/PATIENTS: From a cohort of 78 patients with advanced NSCLC enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 43 patients have been considered for this sub-analysis because of the availability of samples. Before and during nivolumab administration, clinical information and blood samples were collected and resistin, matrix metalloproteinase (MMP)-8, MMP-9, and myeloperoxidase were evaluated by enzyme-linked immunosorbent assay (ELISA). RESULTS: Median age was 71 with a prevalence of males and former smokers. Median resistin levels presented a peak at cycle 2 and then dropped down until the last cycle. Resistin correlated with all neutrophil degranulation products at cycle 1 (except for MMP-9) and at cycle 2 as well as with white blood cells and neutrophils. By a ROC curve analysis, a resistin value at cycle 2 of 19 ng/mL was tested as the best cut-off point for OS. Kaplan-Meier analysis demonstrated that patients above the resistin cut-off experienced a reduced OS (median OS 242.5 vs. 470 days, p = 0.0073), as confirmed by Cox proportional hazards regression analysis. CONCLUSIONS: Resistin levels > 19 ng/mL at the time of the second cycle of nivolumab treatment independently predict a reduced OS in patients with advanced NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/blood , Lung Neoplasms/blood , Nivolumab/therapeutic use , Resistin/blood , Aged , Antineoplastic Agents, Immunological/therapeutic use , Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Non-Small-Cell Lung/mortality , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/immunology , Lung Neoplasms/mortality , Male , Middle Aged , Neutrophils/cytology , Prognosis , Prospective Studies , Survival Rate , Treatment Outcome
7.
Rev. peru. oftalmol ; 9(1): 57-62, 1983. tab, ilus
Article in Spanish | LILACS, LIPECS | ID: lil-107232

ABSTRACT

Se ha realizado la evaluación oftalmológica en 100 pacientes portadores con el diagnóstico clínico de Esclerosis Sistémica, complementando el trabajo con el estudio Sialográfico de la glándulas salivares menores, en algunos de ellos. Se hace el reporte de la correlación de los hallazgos clínicos, radiográficos, obteniéndose los resultados mencionados en el desarrollo del trabajo. Se comentan los resultados obtenidos en relación con las referencias bibliográficas de los especialistas en esta materia


Subject(s)
Scleroderma, Systemic/diagnosis , Biopsy , Sialography/statistics & numerical data , Parotid Gland , Salivary Glands , Hospitals, State
SELECTION OF CITATIONS
SEARCH DETAIL